Autor: |
Eitan Amir, Joseph Kim, Christopher Chan, Alejandro Meraz-Muñoz, Pamela Ng, Carmen Avila-Casado, Claire Ragobar, Ron Wald, Abhijat Kitchlu |
Jazyk: |
angličtina |
Rok vydání: |
2020 |
Předmět: |
|
Zdroj: |
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020) |
Druh dokumentu: |
article |
ISSN: |
2051-1426 |
DOI: |
10.1136/jitc-2019-000467 |
Popis: |
Background Immune checkpoint inhibitors (ICPi) are a novel and promising anti-cancer therapy. There are limited data on the incidence, risk factors and outcomes of acute kidney injury (AKI) in patients receiving ICPi.Methods We conducted a cohort study of patients receiving ICPi at our center between 2010 and 2017 via electronic health record. The primary outcome was AKI (increase of >50% from baseline serum creatinine (sCr)). Risk factors for AKI were assessed using logistic regression. Survival among those with and without AKI was compared using the Kaplan-Meier method.Results Among 309 patients on ICPi, 51 (16.5%) developed AKI (Kidney Disease Improving Global Outcomes (KDIGO) stages 1: 53%, 2: 22%, 3: 25%). AKI was associated with other immune-related adverse events (IRAE) (OR 3.2, 95% CI 1.6 to 6; p |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|